Focus on Anticoagulation Care

Back to articles

Do AMPLIFY trial results signal the beginning of the end for warfarin?

KEY POINT

Apixaban (Eliquis—Bristol–Myers Squibb, Pfizer), administered in a fixed-dose regimen for 6 months, was noninferior to conventional therapy (enoxaparin plus warfarin) for treatment of acute venous thromboembolism (VTE), with significantly less bleeding.

SOURCES

Agnelli G et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;Epub ahead of print.

Cushman M. Treating acute venous thromboembolism: shift with care [editorial]. N Engl J Med. 2013;Epub ahead of print.